Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

Next Previous
X
Search
Trial Profile

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BH-200 (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OLIVE
  • Sponsors HMNC Brain Health

    • Most Recent Events

    • 20 Jun 2023 According to a MNC Brain Health media release, company announced that first patient has been enrolled.
    • 30 Mar 2023 Status changed from planning to recruiting.
    • 20 Oct 2022 According to an HMNC Brain Health media release, the company has raised an EUR 14.3 million in a funding series. These funds will be utilized in the development of the Nelivabon program, including this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top